Ono Pharmaceutical Co., Ltd. (TYO:4528)
Japan · Delayed Price · Currency is JPY 2,533.50
+1.50 (0.06%)
Apr 7, 2026, 11:30 AM JST
Ono Pharmaceutical Employees
Ono Pharmaceutical had 4,287 employees as of March 31, 2025. The number of employees increased by 434 or 11.26% compared to the previous year.
Employees
4,287
Change (1Y)
434
Growth (1Y)
11.26%
Revenue / Employee
118.81M JPY
Profits / Employee
14.56M JPY
Market Cap
1.19T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 4,287 | 434 | 11.26% |
| Mar 31, 2024 | 3,853 | 92 | 2.45% |
| Mar 31, 2023 | 3,761 | 74 | 2.01% |
| Mar 31, 2022 | 3,687 | 80 | 2.22% |
| Mar 31, 2021 | 3,607 | 47 | 1.32% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Otsuka Holdings | 37,758 |
| Daiichi Sankyo Company | 19,765 |
| Astellas Pharma | 13,643 |
| Chugai Pharmaceutical | 7,872 |
| Kyowa Kirin | 5,161 |
| Santen Pharmaceutical | 3,849 |
| JCR Pharmaceuticals | 987 |
| Perseus Proteomics | 32 |
Ono Pharmaceutical News
- 11 days ago - Ono Pharma Submits Application For Manufacturing And Marketing Approval Of Ripretinib - Nasdaq
- 11 days ago - Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan - Business Wire
- 12 days ago - Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights - Benzinga
- 5 weeks ago - Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology - Business Wire
- 6 weeks ago - Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL - Business Wire
- 3 months ago - Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical - GlobeNewsWire
- 4 months ago - Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting - Business Wire
- 5 months ago - Deciphera Announces the Opening of a New Office in Zug, Switzerland - Business Wire